Brief: Biohaven Enrolls First Patient Into Phase 2/3 Trial In Early Parkinson's Disease
29/05/2025 13:04
May 29 (Reuters) - Biohaven Ltd BHVN.N: BIOHAVEN ENROLLS FIRST PATIENT INTO PHASE 2/3 TRIAL IN EARLY PARKINSON'S DISEASE, TARGETING NEUROINFLAMMATION WITH NOVEL BRAIN-PENETRANT TYK2/JAK1 INHIBITOR Source text: ID:nPn129QSGa Further company coverage: BHVN.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean